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Summary In the present study we demonstrate that Aza-dC in combination with Amsacrine has major
antileukaemic properties in patients who have not already received extensive Ara-C therapy. Eight out of 11
patients in their first relapse of acute leukaemia achieved complete remission. Cross resistance between Ara-C
and Aza-dC was revealed by the lack of antileukaemic activity in five patients with with Ara-C resistant
leukaemia. Combination therapy with Aza-dC/Ams-acrine induced a considerable period of a granulo-
cytopenia (28-35 days), while the toxic effect on erythro- and megakaryopoiesis was comparable to that
reported for high dose Ara-C/Amsacrine chemotherapy. Remarkable is the long disappearance time for
leukaemic blast cells in bone marrow, i.e. 3-5 weeks in some cases. Analysis of cell membrane markers
showed a loss of the early differentiation antigens CD34 and CD33 from leukaemic bone marrow cells after 7
days of Aza-dC treatment, which is suggestive of leukaemic cell differentiation. In the small group of patients
tested for DNA hypomethylation no association existed between the degree of hypomethylation and clinical
response. Non-haematologic side effects were considerable in patients receiving the highest dosages of Aza-dC
and consisted of severe, although usually reversible, gastrointestinal and neurological complications. In
comparison with Ara-C, Aza-dC causes less nausea and vomiting and is therefore better tolerated.
5-Aza-2-deoxycytidine (Aza-dC), an analogue of deoxycy-
tidine, has shown antineoplastic activity against some murine
and human leukaemias (Momparler & Gonzales, 1978; Ves-
ely & Cihak, 1977; Momparler et al., 1985). To acquire
cytotoxic activity, Aza-dC has to be phosphorylated into its
triphosphate form, Aza-dCTP, by kinase enzymes of the
salvage pathway for nucleotide synthesis. This parallels the
metabolism of another pyrimidine analogue, Arabinofurano-
syl cytosine (Ara-C).
After incorporation into DNA, as a fraudulent cytosine
base, Aza-dC induces hypomethylation of DNA (Bouchard
et al., 1983), which has been associated with altered gene
expression (Ley et al., 1982), induction of differentiation
(Creusot et al., 1982; Momparler et al., 1985) and probably
cell death. The mechanisms by which Aza-dC induces cyto-
toxicity are entirely speculative. Some possible mechanisms
are: loss of clonogenic potential due to differentiation induc-
tion in leukaemic cells, uncoordinated gene expression that is
not compatible with cell cycle progression, and loss of DNA
integrity due to Aza-dC incorporation (Wilson et al., 1983).
Aza-dC is not an inhibitor of DNA synthesis like Ara-C;
therefore its S-phase specific cytotoxic activity is not self-
limiting (Chabot & Momparler, 1986; Richel et al., 1988). In
an animal model of myelocytic leukaemia, the Brown Nor-
way rat leukaemia model (BNML/0), we previously showed
that Aza-dC exhibits a more distinct antileukaemic activity
than Ara-C (Richel et al., 1988). In the Ara-C resistant
BNML model (BNML/Ara-C) we demonstrated cross resis-
tance between Ara-C and Aza-dC. To evaluate the activity of
Aza-dC in human leukaemia we treated 16 patients with
relapsed or resistant acute leukaemia with Aza-dC.
Materials and methods
Patient characteristics
Sixteen patients were treated with Aza-dC (Table I). Five
patients (AML 4, ALL 1) unresponsive to high or inter-
mediate dose Ara-C were considered highly refractory.
Eleven patients (AML 10, ALL 1) in their first relapse of
acute leukaemia after a minimum of 6 months of complete
remission (CR) were considered potentially sensitive. The
median age of these 16 patients was 38.5 years.
Drugpreparation and administration
Aza-dC was kindly supplied by Mack Pharmaceutical Indus-
try (Ilertissen, FRG). Vials contained 50 mg of the drug,
which had been dissolved in 15 ml 0.02 M KH2PO4 adjusted
to pH 7.0 with NaOH and freeze dried.
The prescribed dose was diluted with 0.9% NaCl solution
for administration by intravenous infusion. Because Aza-dC
decomposes by about 10% after 5 h at room temperature,
the 6-h infusion was divided into two infusions of 3 h each.
Treatment schedule (Table I)
Five patients received Aza-dC monotherapy: 250-500
mg m-2 twice daily for 3-6 days. Eleven patients were
treated with the following chemotherapy regimen: Aza-dC
(125-250mgm2) as a 6-h infusion twice daily for 6 days
and Amsacrine (120 mg m-2) as a 1-h infusion on days 6 and
7.
Aza-dC determination in plasma
The assay for Aza-dC is a slight modification of the assay
described by Lin et al., 1985. The samples were analysed by
high performance liquid chromatography (HPLC).
Immunophenotyping
Leukaemic bone marrow cells, harvested on days 0 and 7 of
the chemotherapy schedule, were separated by Ficoll-Hypo-
que gradient (specific gravity 1.077). Cell surface antigens
were detected by standard immunofluorescence using a panel
of monoclonal antibodies (Mo Abs) representative of cluster
groups described by the International Workshops on Human
Leucocyte Differentiation Antigens (Pallesen et al., 1987).
Fluorescence activity was analysed by microscopy.
Myeloid leukaemic cells were tested for CD34, CD33,
CD15, CD lla,b,c, HLA-DR, VIM2 and lymphoid leukaemic
cells for CD34, CDE2, CD7, CD1O, CDl9, CD20, HLA-DR,
IgM, Kappa, Lambda (surface and cytoplasmic) and TdT.
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Table I Patient characteristics
Patient FIM Age Diagnosis Treatment/schedule
Refractory leukaemia
1 F 22 AML, MI, I Aza-dC 250mg m-2 x 6
1st relapse after ABMT
refractory to internediate dose Ara-C
2 M 26 AML, M,; 4th relapse I Aza-dC 500 mg m-2 x 6
3 F 42 ALL, 3rd relapse I Aza-dC 250mgm2 x 12
4 F 48 AML, M2; 2nd relapse I Aza-dC 500mgm2 x 12
5 M 20 ALL; refractory to HD Ara-C II
Relapsed leukaemia
6 F 23 AML, M4 I Aza-dC 250mgm2 x 12
1st relapse after ABMT
7 F 56 AML, M2; 1st relapse II
8 M 61 AML, M undiff; 1st relapse II
9 M 51 AML, M3; 1st relapse II
10 F 63 AML, MI; 1st relapse II
11 F 61 AML, M2; 1st relapse II
12 F 52 AML, M4; 1st relapse II
13 M 39 AML, M3; 1st relapse II
14 M 55 AML, M2; 1st relapse II
15 M 45 ALL; 1st relapse II
16 F 29 AML, M4; 1st relapse II
MI-M6 FAB-classification. I: Monotherapy with Aza-dC: 250-500mgm-2 twice daily for 3-6 days. II:
Combination chemotherapy: 125mg m-2 Aza-dC as a 6-h infusion twice daily for 6 days and 120mg m-2
Amsacrine on days 6-7, except patient 7, who received 250mgm-2-Aza-dC, every 6 h as monotherapy.
Methylation assay
Leukaemic bone marrow cells collected in RPMI 1640 me-
dium with heparin were separated by Ficoll-Hypoque gra-
dient (specific gravity 1.077). Cell nuclei were isolated prior
to DNA isolation (Colly et al., 1990). DNA isolation was
performed by a modification of a method described by
(Davis et al., 1980). DNA was degraded to nucleosides with
digestion enzymes: DNAase I, alkaline phosphatase type III-
N and Snake Venom Phosphodiasterase (Sigma) (Colly et al.,
1990). Incubation time with these enzymes was 4 h at 37°C.
After digestion an amount was mixed with methanol and
dried by N2/40°C. The residue was suspended in the mobile
phase. 5 Methyl deoxycytidine (5-meth dC) and dC were
analysed by high pressure liquid chromatography (HPLC)
using a 3ym hypersil silica column (46 x 120 mm) with
480 ml CH CL3, 116 ml methanol and 7 ml 0.5 M NH4
H COO (Ph 3.3) as the mobile buffer. The absorbance of the
eluted compound was determined at 280 nm (by spectroflow
773 krakos). The percentage 5-meth dC was calculated as:
5-meth dC = mol 5-meth dC/mol (5-meth dC + dC) x 100%.
Results
Sixteen patients were treated with Aza-dC. Four out of five
patients with resistant leukaemia received Aza-dC as mono-
therapy and one received Aza-dC in combination with Amsa-
crine. Only two of these five patients exhibited a slight reduc-
tion in leukaemic cells in the bone marrow. Ten out of 11
patients with sensitive leukaemia received Aza-dC in com-
bination with Amsacrine for 2 days and one patient received
Aza-dC as monotherapy.
Eight out of this group of 11 patients achieved complete
remission (73%), two partial remission; one patient died due
to toxicity (Table II). Four patients in CR received one
consolidation course consisting of the same schedule (Aza-
dC/Amsacrine), except that Aza-dC was given for 4 instead
of 6 days. Four out of the eight CR patients relapsed at 11,
8, 7 and 1.5 months, respectively. One patient died 6 weeks
after CR, due to a myocardial infarction. Three patients are
still in CR at 12, 7 and 2 months, respectively.
In comparison with Ara-C, Aza-dC caused less nausea and
vomiting and is therefore better tolerated.
Haematological toxicity
Aza-dC induced a considerable period of myelo-suppression
(Table III). A remarkable finding is the phenomenon that the
period of a granulocytopenia after the less intensive con-
solidation course was 10 days longer than after the induction
course. Erythro- and mega-karyopoiesis were spared rela-
tively to granulopoiesis. Leukaemic cell reduction in the bone
marrow takes much longer than observed in historical con-
trols treated with high dose Ara-C (Figure 1).
Non-haematological toxicity
This consisted of transient sterile peritonitis (severe in three
and moderate in three patients) and transient increases in the
transaminase and bilirubin levels in one patient. One patient
died due to intestinal bleeding; at autopsy a large diver-
ticulum in the jejunum was found (the source of the bleed-
ing). Two patients developed hemiparesis 7 and 10 days after
chemotherapy, respectively; a CT-scan revealed no focal
abnormalities.
In one case recovery was nearly complete within 2 weeks:
in the other it was partial. Three patients experienced a
period of somnolence, which began during the course of
chemotherapy and persisted until about 3 days after the last
Aza-dC infusion.
Pharmacokinetic studies
Aza-dC plasma levels were determined during the 6-h in-
fusion and after discontinuation of the infusion. When Aza-
dC was infused at a rate of 21 mgm-2 hour- (125 mg' m-l
6 h-1), the mean plasma concentration was 0.6-1.2I1M. At
dose rates of 42mgm-2 hour-' and 84mgm-2 hour ', the
plasma levels were about 2JM and 5ELM, respectively. After
discontinuation of the infusion the plasma half-life was
8-14 min.
DNA methylation studies (Table IV)
The methylation level of total DNA in leukaemic bone mar-
row cells from six patients was measured before (day 0) and
after in vivo Aza-dC therapy (day 7).
Only bone marrow samples with more than 70% leukaemic
cells were used. Because of the slow blast cell reduction, the
percentages of leukaemic bone marrow cells on days 0 and 7146 D.J. RICHEL et al.
Table II Results of Aza-dC treatment
Patient
Refractory leukaemia
1 NR
2 NR
3 NR
4 NR
5
Outcome Complications
No
No
No
Reversible hemiparesis; peritonitis;
Somnolence
No NR
Relapsed leukaemia
6 PR (BM blasts 80%-*7%)
7 CR
8 CR
9 CR
10 CR
11 CR
12 PR (BM blasts 75%-*8%)
13 CR
14 Failure
15 CR
16 CR
Peritonitis; somnolence
Peritonitis; somnolence, hemiparesis
Moderate peritonitis
Moderate peritonitis
No
No
No
Fever of undetermined origin, hyperbilirubinaemia
Death due to gastrointestinal bleeding
Moderate peritonitis
No
Table III Haematological recovery from day 1 after chemotherapy, in days
Aza-dC/Amsacrine Ara-C/Amsacrine
Induction course Consolidation course Induction course
n= 1I N=4 n= 10
Granulocyte
>0.5 x 10-91-' 25 (18-29) 35 (30-30) 19 (15-22)
Reticulocyte
> 10%o 29 (15-24) 19 (17-21) 20 (16-22)
Platelet transfusion
Independent 18 (16-20) 16 (13-18) 19 (14-21)
Historical controls: Ara-C/Amsacrine: Ara-C 1000 mgm-2 x 12; Amsacrine
120mgm-2 x 2 (no. 14).
Surface marker studies (Table V)
A complete panel of monoclonal antibodies for cluster
differentiation antigens were used to test leukaemic BM cells
from seven patients before and 7 days after start of chemo-
therapy. Because the percentages of leukaemic cells on days 0
and 7 were similar in six cases, a comparison of the cellular
immunophenotypes before and after Aza-dC treatment could
be made.
Three patients (5, 11 and 16) showed a loss of the early
differentiation antigens CD33, and/or CD34. The other three
patients did not exhibit significant changes in antigen expres-
sion. Patient 5 with resistant ALL lost not only CD34 but
also the B cell markers (CD19, CD20 and CD22, although
O- 1 2 3 4 5 6 reexpression of these markers occurred on day 21.
Aza-dC/Amsacrine WEEKS For patients 11 and 16 with AML a slight increase in
CD 11 myeloid differentiation antigens was demonstrated. No
Figure 1 Disappearance ofleukaemic blast cells from bone mar- change in the other markers (CD's, MPO, TdT, HLA-DR
row after Aza-dC/Amsacrine chemotherapy. Each symbol repre- and membrane or cytoplasmic immunoglobulins) was found.
sents one patient.
were only slightly different in six patients. In all cases there
was a decline in DNA methylation levels, which ranged from
15% to 49%. In this small patient group there was no
relation between the degree of hypomethylation and the
clinical response. For patients 5 and 12, with resistant disease
and partial remission, methylation inhibition was 49% and
41%, respectively, whereas patients 10, 11, 13 and 15, who
achieved complete remission, showed a methylation inhibi-
tion of 15% to 28%. Patient 5, with resistant ALL, exhibited
no reduction of leukaemic bone marrow cells on days 6, 14
and 21, whereas methylation decreased to ± 50% on day 6
and returned to the original level on day 21. In two patients
tested during leukaemic relapse, methylation was at pre-
treatment levels.
Discussion
In the present study we demonstrate that Aza-dC is not
effective in patients with Ara-C resistant leukaemia. This
confirms the observation of cross resistance between Aza-dC
and Ara-C in the Ara-C resistant BNML model. Considering
the fact that impaired phosphorylation of Ara-C is the
underlying mechanism of resistance in the rat leukaemia
model (Richel et al., submitted for publication), cross resis-
tance between Ara-C and Aza-dC is not surprising, since
both drugs initially follow the same metabolic pathway. In
human leukaemia Ara-C resistance is probably a hetero-
geneous phenomenon, but the lack of antileukaemic activity
of Aza-dC in Ara-C refractory patients implies a mechanism
involving early intra-cellular metabolic events. The failure ofANTI-LEUKAEMIC EFFECT OF 5 Aza-dC 147
TableIV Methylation levelsbefore (day0)andafter(day6)invivo treatment
with Aza-dC
Day 0 Day 7 Methylation At relapse
Patient 5-meth dC Inhibition Day 21 % 5-meth dC
5 4.1 2.1 49% 4.1
10 4.2 3.3 22% -
11 4.8 3.5 28% 4.5
12 4.4 2.6 41% -
13 4.9 4.2 15% -
15 4.9 3.1 27% 5.0
Table V Changes in immunophenotype after Aza-dC chemotherapy
Patient 5 11 16
Diagnosis ALL AML AML
Clin. response R CR CR
% Methylation inhibition 49 28 -
Days 0 7 0 7 0 7
% BM blast 90 70 90 80 30 40
% Blood dilution 10 15 5 15 10 5
% CD34 81 1 0 1 25 2
% CD33 0 0 60 1 71 1
%CDlla 0 16
% CDllb <1 35 16 47
% CD11c 0 14
% CD19 88 13
% CD20 34 4
% CD22 71 0
Days 0 and 7: before and after start Aza-dC chemotherapy. R:
resistantleukaemia, CR: completeremission, CD: clusterdifferentiation
antigen. A complete panel of MoAb was tested, only CDs with
significant changes in expression are given.
Aza-dC in patients who had already undergone extensive
treatment with Ara-C (Momparler et al., 1985; Debusscher
1989) is probably also due to cross resistance between Ara-C
and Aza-dC.
To prove the effectiveness of Aza-dC, as shown in the
Ara-C sensitive BNML model (Richel et al., 1988), we
selected a group of patients in the first relapse of acute
leukaemia after a minimum period of 6 months of unmain-
tained remission. High-dose Ara-C (HD-Ara-C)/Amsacrine
treatment of a similar group AML patients in their first
relapse led to CR in approximately 60% of cases (Peters et
al., 1988).
We designed a protocol based on administration of Aza-
dC as a 6-h infusion twice daily for 6 days. Initially we had
chosen for a cumulative Aza-dC dose of 3000 mgm-2 during
a total infusion time of 72 h. This was based upon the results
of clinical studies of Momparler (Momparler et al., 1985), in
which the maximal cumulative Aza-dC dose was about
2600 mg -2 during a total infusion time of 60 h. Because of
neurological and gastrointestinal toxicity the total Aza-dC
dose was lowered to 1500 mgm-2 during the same infusion
time of 72 h. Because Ara-C containing chemotherapy regi-
mens are always combined with an anthracycline or Amsa-
crine and to ensure the best chance of remission, we added 2
days of Amsacrine to this schedule. We realise that the
addition of Amsacrine, although only two doses were given,
makes it more difficult to evaluate the contribution of Aza-
dC to the response and toxicity of the combined regimen. On
the other hand this schedule can be compared to the stan-
dard schedule Ara-C/Amsacrine.
Eight out of 11 patients achieved CR (73%). The median
duration of remission for these patients was approximately 7
months. Although the patient group is rather small, these
data suggest that Aza-dC/Amsacrine is as effective as high-
dose Ara-C/Amsacrine (Peters et al., 1988).
The haematological toxicity, as it affected erythro- and
megakaryopoiesis, was comparable to that of the high-dose
Ara-C/Amsacrine regimen; however, the effect on granulo-
poiesis was more profound, resulting in agranulopenic per-
iods of 25 and 35 days (Table I) after the induction and
consolidation courses, respectively. The differential toxic
effects on various haematopoietic cell types is a subject for
further research.
A remarkable observation is that the disappearance time
for leukaemic blasts in the bone marrow after treatment with
Aza-dC/Amsacrine was much longer than that found for
historical controls treated with high dose Ara-C/Amsacrine.
This phenomenon points to a different mechanism of cyto-
toxicity compared to that of Ara-C, Aza-dC does not induce
inhibition of DNA synthesis, and cytotoxicity only becomes
manifest after two cell cycles.
Non-bacterial peritonitis, which became evident about 2-7
days after chemotherapy, was the most frequent non-haema-
tological side-effect. Severe peritonitis were only seen in
patients receiving Aza-dC in dosages of 250-500mgm2.
The neurological complications hemiparesis and somnolence
were also restricted to patients on these higher dosages. The
central nervous system toxicity of Ara-C is of a complete
different order and consists mainly of extracerebral toxicity,
especially seen at doses higher than 2000mgm2. In two
other clinical studies (Momparler et al., 1986; Debusscher et
al., 1989) this kind of toxicity was not encountered. These
complications are probably related to the high Axa-dC plas-
ma levels. In Momparler's study plasma levels of 0.8-1.4gM
were obtained for 60h, while in our study 250-500mgM2
Aza-dC resulted in plasma levels of 1.8-51JM for 72h. A
dosage of 125 mgm-2 Aza-dC yielded plasma levels of
0.6-1.2tM. Although only a limited number of patients has
been given this lower dose, toxicity seems to be reduced. In
the small group of patients tested for DNA methylation no
association existed between the degree of hypomethylation
and clinical response.
Although the loss of the stem cell marker CD34 and the
early myeloid progenitor marker CD33 in three patients after
Aza-dC is suggestive of leukaemic cell differentiation, further
research is needed to elucidate this interesting phenomenon,
especially with regard to the increased expression of markers
representing more mature phenotypes.
The data in this report demonstrate that Aza-dC combined
with Amsacrine according to the schedule described above
has a major antileukaemic effect in patients who have not
previously undergone extensive Ara-C therapy. This com-
bination is probably as effective as HD-Ara-C/Amsacrine.
Drug-related toxicity, especially at the higher dosages, was
considerable but generally reversible. When an Aza-dC dose
of 125 mgm2 was administered 12 times as a 6h infusion
toxicity was acceptable.
More experience with Aza-dC for remission and/or con-
solidation therapy is needed to find out whether this drug
will gain a place as therapy-of-choice for acute leukaemia.148 D.J. RICHEL et al.
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